CERECOR - Trademark Details
Status: 733 - Fourth Extension - Granted
Image for trademark with serial number 88424859
Serial Number
88424859
Word Mark
CERECOR
Status
733 - Fourth Extension - Granted
Status Date
2021-12-01
Filing Date
2019-05-10
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s) Typeset
Design Searches
011102 - Partial moons, including half moons and crescent moons.
Published for Opposition Date
2019-10-08
Attorney Name
Law Office Assigned Location Code
L70
Employee Name
BUTLER, MIDGE FAE
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of a crescent shaped figure with various lines throughout and the word "CERECOR" written within the crescent with the points of the crescent falling on the "ER" of the word.
Goods and Services
Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-05-25
Primary Code
005
Current Trademark Owners
Party Type
21 - 1st New Owner After Publication
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Type
21 - 1st New Owner After Publication
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Paul J. Kennedy
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship TypeReel Number
Prior Registration4822297
Trademark Events
Event DateEvent Description
2019-05-14NEW APPLICATION ENTERED IN TRAM
2019-05-25NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2019-05-28NOTICE OF DESIGN SEARCH CODE E-MAILED
2019-07-25ASSIGNED TO EXAMINER
2019-08-01PRIORITY ACTION WRITTEN
2019-08-01PRIORITY ACTION E-MAILED
2019-08-01NOTIFICATION OF PRIORITY ACTION E-MAILED
2019-08-30TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-08-30CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-08-30TEAS/EMAIL CORRESPONDENCE ENTERED
2019-09-03APPROVED FOR PUB - PRINCIPAL REGISTER
2019-09-05ASSIGNED TO LIE
2019-09-18NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2019-10-08PUBLISHED FOR OPPOSITION
2019-10-08OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2019-12-03NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2020-04-28TEAS CHANGE OF OWNER ADDRESS RECEIVED
2020-04-28TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2020-04-28ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2020-04-28TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
2020-04-28TEAS CHANGE OF CORRESPONDENCE RECEIVED
2020-04-28APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2020-05-27CASE ASSIGNED TO INTENT TO USE PARALEGAL
2020-05-27APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2020-06-02TEAS WITHDRAWAL OF ATTORNEY RECEIVED
2020-06-02WITHDRAWAL OF ATTORNEY GRANTED
2020-06-02TEAS CHANGE OF OWNER ADDRESS RECEIVED
2020-06-02TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2020-06-02ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2020-06-02TEAS CHANGE OF CORRESPONDENCE RECEIVED
2020-06-02APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2020-06-03TEAS EXTENSION RECEIVED
2020-06-03EXTENSION 1 FILED
2020-06-03EXTENSION 1 GRANTED
2020-06-05NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2020-12-02TEAS EXTENSION RECEIVED
2020-12-02EXTENSION 2 FILED
2020-12-07EXTENSION 2 GRANTED
2020-12-08NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-05-20TEAS EXTENSION RECEIVED
2021-05-20EXTENSION 3 FILED
2021-05-20EXTENSION 3 GRANTED
2021-05-22NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-09-22AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
2021-12-01TEAS EXTENSION RECEIVED
2021-12-01EXTENSION 4 FILED
2021-12-01EXTENSION 4 GRANTED
2021-12-03NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED